Clinical Trials on Treatment of Overactive Bladder

Total 1554 results

Pfizer

Completed

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Treatment of Overactive Bladder

United States
Pfizer

Completed

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Treatment of Overactive Bladder

United States
BlueWind Medical

Recruiting

BlueWind RENOVA iStim™ System for the Treatment of OAB (OASIS)

Treatment of Patients Suffering From Overactive Bladder (OAB)

United States, Belgium, Netherlands, United Kingdom
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Centre Hospitalier Universitaire Dijon

Unknown

Retrospective Study of Prescribed Physical Activity in Patients With Overactive Bladder Syndrome Monitored Within the Pelvi-perineology Network in Dijon: Evaluation of Prescription Compliance and Impact on Quality of Life (HAV-AP)

iOAB= Idiopathic Overactive Bladder

France
Pfizer

Completed

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency

United States
Takeda

Completed

Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome

Overactive Bladder Syndrome
MedtronicNeuro

Completed

A Cost Analysis of Interstim Therapy

Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

Pharmacokinetics of Mirabegron | Overactive Bladder (OAB)

Korea, Republic of, Russian Federation, Turkey
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Ankara Yildirim Beyazıt University

Completed

Comparison of Different Treatments for Overactive Bladder Syndrome

Overactive Bladder | Overactive Detrusor | Overactive Bladder Syndrome

Turkey
University of Zagreb

Not yet recruiting

Impact of OAB Symptoms on Quality of Life in Croatia (OAB-CRO)

Overactive Bladder

Croatia
Pamukkale University

Completed

Intravaginal Electrical Stimulation in Idiopathic Overactive Bladder

Electrical Stimulation | Idiopathic Overactive Bladder | Bladder Training

Turkey
Pfizer

Completed

Drug Use Investigation for Toviaz

Overactive Bladder (OAB)
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Detrol LA In Men With Overactive Bladder.

Overactive Bladder (OAB)

United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
Medstar Health Research Institute
Columbia University; University of Michigan; University of New Mexico; Methodist...

Terminated

PTNS vs Botox of Refractory OAB (TROOP)

Overactive Bladder (OAB)

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) (PREFER)

Overactive Bladder (OAB)

United States, Canada
Merck Sharp & Dohme LLC

Terminated

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Overactive Bladder | Overactive Urinary Bladder
Loyola University
Astellas Pharma Inc

Completed

Validation of a Real-time Urodynamic Measure of Urinary Urgency

Overactive Bladder Syndrome

United States
Beijing Pins Medical Co., Ltd

Unknown

A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique

Refractory Overactive Bladder
Maastricht University Medical Center

Unknown

Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Netherlands
Pfizer

Completed

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence

United States
Astellas Pharma Singapore Pte. Ltd.

Completed

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Overactive Bladder (OAB)

Korea, Republic of, Australia
Velicept Therapeutics, Inc.

Completed

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

Healthy Subjects, Overactive Bladder
Augusta University

Not yet recruiting

Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial

Overactive Bladder | Overactive Bladder Syndrome
Uro-1 Medical

Recruiting

Use of Repris Needle in Bladder Injection

Overactive Bladder Syndrome

United States
Fisiocore LC,SL

Recruiting

Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.

Overactive Bladder Syndrome

Spain
National Taiwan University Hospital

Completed

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Overactive Bladder Syndrome

Taiwan
National and Kapodistrian University of Athens

Completed

Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)

Overactive Bladder (OAB)

Greece
Taipei Medical University Shuang Ho Hospital

Completed

Effect of Ureteral Stents Length and Location on Related Symptom

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Taiwan
Astellas Pharma Singapore Pte. Ltd.

Completed

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Overactive Bladder (OAB)

Korea, Republic of, Taiwan
Ataturk Training and Research Hospital

Unknown

Effects of Kinesio Taping Application in Women With Overactive Bladder

Overactive Bladder Syndrome

Turkey
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Catalan Institute of Health

Completed

Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron

Overactive Bladder Syndrome
Buddhist Tzu Chi General Hospital

Unknown

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Overactive Bladder Syndrome

Taiwan
University of Oklahoma

Completed

Vaginal Electrical Stimulation Versus Neuromodulation (Estim)

Refractory Overactive Bladder

United States
Astellas Pharma Inc
GlaxoSmithKline

Withdrawn

A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication

Overactive Bladder (OAB)
National Taiwan University Hospital

Unknown

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Overactive Bladder Syndrome

Taiwan
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Peripheral Electrical Stimulation for the Treatment of Overactive Bladder (PESTOB)

Idiopathic Overactive Bladder

United Kingdom
National Taiwan University Hospital

Unknown

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Overactive Bladder Syndrome

Taiwan
Pfizer

Completed

Fesoterodine "add-on" Male Overactive Bladder Study

Overactive Bladder Syndrome

United States, Canada, Greece, Brazil, Korea, Republic of, Singapore, Poland, India, Norway, Slovakia, Spain, Belgium, Philippines, Netherlands, Sweden, Thailand, Malaysia, Germany, Colombia
Avera Pharmaceuticals

Terminated

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Overactive Bladder Syndrome

Netherlands, United Kingdom
Novartis

Completed

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Overactive Bladder Syndrome

United States
Astellas Pharma Singapore Pte. Ltd.

Completed

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Overactive Bladder (OAB)

Korea, Republic of, Australia
Jeil Pharmaceutical Co., Ltd.

Completed

The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Overactive Bladder(OAB)

Korea, Republic of
En Chu Kong Hospital

Completed

Herbal Patch for Overactive Bladder

Overactive Bladder Syndrome

Taiwan
University of California, San Diego

Completed

Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder

Overactive Bladder Syndrome

United States
Beijing Pins Medical Co., Ltd
Beijing Hospital

Unknown

Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)

Refractory Overactive Bladder

China
University of Zurich

Completed

Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

Overactive Bladder Syndrome

Switzerland
Novartis

Completed

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Overactive Bladder Syndrome

United States

Clinical Trials on Treatment of Overactive Bladder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations